Abstract
The production of reactive oxygen species (ROS) from the inner mitochondrial membrane is one of many fundamental processes governing the balance between health and disease. It is well known that ROS are necessary signaling molecules in gene expression, yet when expressed at high levels, ROS may cause oxidative stress and cell damage. Both hypoxia and hyperoxia may alter ROS production by changing mitochondrial Po2 (PmO2). Because PmO2 depends on the balance between O2 transport and utilization, we formulated an integrative mathematical model of O2 transport and utilization in skeletal muscle to predict conditions to cause abnormally high ROS generation. Simulations using data from healthy subjects during maximal exercise at sea level reveal little mitochondrial ROS production. However, altitude triggers high mitochondrial ROS production in muscle regions with high metabolic capacity but limited O2 delivery. This altitude roughly coincides with the highest location of permanent human habitation. Above 25,000 ft, more than 90% of exercising muscle is predicted to produce abnormally high levels of ROS, corresponding to the “death zone” in mountaineering.

Introduction
It is well accepted that cellular hypoxia [1–4] triggers a constellation of biological responses involving transcriptional and post-transcriptional events [5,6] through activation of cellular oxygen sensors. This includes generation of reactive oxygen species (ROS). Yet, current knowledge on the quantitative relationships between mitochondrial Po2 (PmO2), hypoxia-induced cellular events, and on the release of ROS from the inner mitochondrial membrane, is minimal. For example, how low PmO2 must be to trigger abnormally high ROS generation has not yet been identified. Furthermore, the levels of PmO2 at rest and during exercise are unknown, although myoglobin-associated Po2 has been measured in intact exercising humans [7,8], and is reported to be 3–4 mm Hg, implying that PmO2 is likely even lower. There are promising new approaches being developed to in vivo assessment of PmO2 [9].

Recently, we extended a prior model describing O2 transport from the air to the mitochondria as an integrated system limiting maximal oxygen uptake \( V_{\text{O2 max}} \) [10,11] to also include the contribution to overall impedance to O2 flow from the above-zero PmO2 required to drive mitochondrial respiration [12]. This was accomplished by including an equation for the hyperbolic relationship between mitochondrial Po2 and mitochondrial \( V_{\text{O2}} \), as shown by Wilson et al. [13] and confirmed more recently by Gnaiger’s group [14,15]. This has enabled the prediction of PmO2 as a balance between the capacities for muscle O2 transport and utilization [12,16]. In addition, we have expanded this model by now allowing for functional heterogeneity in both lungs and muscle [16], which had previously (and reasonably) been taken to be negligible in health. This was done to enable application to disease states. Since mitochondrial ROS generation is affected by cellular oxygenation, this integrative model may afford the opportunity for better understanding the quantitative relationship between O2 transport, mitochondrial respiration and ROS generation, provided we have an understanding of the relationship between PmO2 and ROS formation.
Recent modeling and experimental studies on mitochondrial ROS production under hypoxia and re-oxygenation [17–19] have proposed an inherent bi-stability of Complex III, i.e. coexistence of two different steady states at the same external conditions: one state corresponding to low ROS production, and a second potentially dangerous state with high ROS production. Temporary deprivation of oxygen could switch the system from low to high ROS production, thus explaining the damaging effects of hypoxia-re-oxygenation. This recently proposed model provides a conceptual basis for the abnormally high ROS production observed both in hypoxia [20,21] and hypoxia [1–4] and has the ability to predict the quantitative relationship between ROS generation and PMO.

In this paper, we build upon these previous but separate models of O2 transport as a physiological system and mitochondrial metabolism as a biochemical system, and have linked them through their common variables, PMO and VO2, establishing one integrated model to predict PMO and mitochondrial ROS production. Specifically, we integrate the physiological model of the oxygen pathway predicting PMO from the balance between O2 transport and mitochondrial O2 utilization [10–12,16] with the model of electron and proton transport in the mitochondrial respiratory chain, and the ROS production associated with this transport [17–19], thereby predicting the rate of ROS production as a function of PMO and VO2. The former model is referred to below as the O2 pathway model, and the latter as the mitochondrial ROS prediction model.

In addition to describing the integrated modeling system, we present estimates of ROS generation in exercising muscle of healthy subjects at different altitudes and at above sea level using O2 transport data from Operation Everest II [22] and published mitochondrial kinetic data in normal human muscle (discussed in [17]). We found that at sea level, O2 transport at maximal exercise is sufficient to keep PMO high enough that mitochondrial ROS generation is not significantly increased. However, exercise at high altitude is predicted to significantly increasing ROS generation, agreeing with experimental data collected under these conditions [23–25].

Materials and Methods

Oxygen pathway model

The modeling of O2 transport and utilization [10–12] adopted in the current article relies on the concept that maximal mitochondrial O2 availability is governed by the integrated behavior of all steps of the O2 transport and utilization system rather than being dominated by any one step. Building on the work of Dejours [26], and Weibel et al [27], it was previously shown [10,11] how each step (ventilation, diffusion across the alveolar wall, circulation, diffusion from the muscle capillaries to the mitochondria, and finally, oxidative phosphorylation itself) contributes quantitatively to the limits to maximum O2 uptake (VO2 max). The model is based on the principle of mass conservation at every step, and uses the well-known mass conservation equations for each step as laid out by Weibel et al [28]. Given the oxygen transport properties of the lungs, heart, blood and muscles, and incorporating the (hypobiotic) mitochondrial respiration curve that relates mitochondrial VO2 to mitochondrial P02 [13–15] the model computes how much O2 can be supplied to the tissues (VO2), and the partial pressures of oxygen at each step (i.e. alveolar (Pao2), arterial (PaO2), venous (PvO2), and mitochondrial (PMO)). This construct [12] leads to a system of five equations, each describing mass conservation equations governing O2 transport (Eqs. (1)–(4)) and utilization (Eq. (5)), with the five unknowns also mentioned above.

\[
\dot{V}_{O2} = V_{I-Flo2} - \dot{V}_{AFAO2} 
\]

\[
\frac{d[O2]}{dt} = \frac{DL}{T_{L}Q} (P_{aO2} - P_{CO2}(t)) 
\]

\[
V_{O2} = Q(C_{aO2} - C_{vO2}) 
\]

\[
\frac{d[O2]}{dt} = \frac{DM}{T_{M}Q} (P_{CO2}(t) - P_{M02}) 
\]

\[
\dot{V}_{O2} = \frac{V_{max} PM_{O2}}{P_{M02} + P_{50}} 
\]

However, this system ignores heterogeneity of ventilation/perfusion (V/Q) ratios in the lung, and heterogeneity of metabolism/perfusion (VO2/Q) ratios in the muscle. This is laid out in detail in [16], and in the current article, consideration of typical, normal degrees of lung and muscle heterogeneity has been incorporated. The original 5-equation model [12] also failed to take into account that not all of the cardiac output flows to the exercising muscles. Allowance for blood flow to, and O2 utilization by, non-exercising tissues has accordingly also now been incorporated into the system described in [16] and is used here.

Parameters of the O2 pathway model

The most complete data set with respect to O2 pathway conductances during exercise at altitude (ventilation (V), cardiac output (Q), lung (DL) and muscle (DM) diffusional conductances, [Hb]) comes from Operation Everest II [22], but even here, measurements were made only at sea level, and at barometric pressures equivalent to four specific altitudes of 15,000 ft., 20,000 ft., 25,000 ft. and 29,000 ft. Because we wished to simulate the entire altitude domain from sea level to the Everest summit, we used the Operation Everest II data to interpolate parameter values at intervening altitudes. Additional input parameters are required for the analysis. These include: a) maximal muscle mitochondrial metabolic capacity (V max), b) mitochondrial P50 i.e., the P02 at which mitochondrial respiration is half-maximal, c) dispersion of ventilation/perfusion ratios in normal lungs, d) dispersion of metabolism/perfusion ratios in muscle, and e) an estimate of total blood flow to non-exercising tissues and their corresponding VO2.

For V max, we chose a value 20% higher than the observed sea level maximal VO2 in the Operation Everest II subjects, and this came to 4.58 L/min. The justification is that in healthy fit subjects, VO2 max is O2 supply-limited at sea level, since it increases when 100% O2 is breathed [29,30]. This demonstrates that mitochondrial metabolic capacity is clearly greater than sea level VO2 max. For mitochondrial P50, a value of 0.14 mm Hg was chosen. This is the mitochondrial P50 value used in the ROS prediction model described below [17–19], and is close to reported values measured in vitro [14,15]. A representative normal level of
ventilation/perfusion heterogeneity (i.e., $\log SD \bar{Q} = 0.5$) was used, since normal subjects display $\log SD \bar{Q}$ values of between 0.3 and 0.6 [31], increasing slightly with exercise. $\log SD \bar{Q}$ is the second moment (dispersion) of the perfusion distribution on a logarithmic scale and has been used to quantify $\bar{V}_{A}/\bar{Q}$ heterogeneity for about 40 years [32–34]. For $\bar{V}_{A}/\bar{Q}$ heterogeneity in muscle, there is very limited information. From a new technique based on near-infrared spectroscopy and currently in development, the corresponding dispersion in muscle appears to be about 0.1 (Vogiatzis et al, J. Applied Physiol, under revision), and this was used.

Finally, to allow for non-exercising tissue perfusion and metabolism we used typical normal resting values of cardiac output and $\bar{V}_{O_{2}}$ (specifically, non-exercising total tissue blood flow equal to 20% of maximal sea level cardiac output, and $\bar{V}_{O_{2}}$ of 300 ml/min).

Mitochondrial ROS prediction model

The mitochondrial ROS prediction model [17–19] considered in this study accounts for: i) Respiratory complex I that oxidizes NADH and reduces ubiquinone ($Q_{o}$, translocating H+; ii) Respiratory complex II that also reduces $Q_{o}$ oxidizing succinate to fumarate; iii) Respiratory complex III, the net outcome of which is to oxidize ubiquinol, reducing cytochrome c and translocating H+; iv) Respiratory complex IV that oxidizes cytochrome c, reducing molecular oxygen to $H_{2}O$ and translocating H+; and, v) The H+ gradient utilization for ATP synthesis in respiratory complex V. NADH consumed by complex I is produced in the several reactions of the TCA cycle leading from pyruvate to succinate, and from fumarate to oxaloacetate.

This model consists of a large system of ordinary differential equations that simulate the processes mentioned above based on the general principle of the law of mass action. Simulating the redox (from reduced/oxidized) reactions between the electron carriers constituting complexes I and III, the model takes into account that the carriers occupy fixed positions and have fixed interactions in the space of a respiratory complex. The variables of this model are the concentrations of redox states of the complex. Each redox state of the complex is a combination of redox states of the electron carriers constituting it. Since a carrier can be in one of the two redox states (reduced or oxidized), the number of variables is $2n$, where $n$ is the number of electron carriers fixed in the space of the complex. The model accounts also various forms of the complexes created by binding/dissociation of ubiquinone/ubiquinol. The other respiratory complexes are accounted for in a simplified form, assuming that the electrons that leave complex III ultimately reduce oxygen. Such a reaction is taken to be a hyperbolic function of oxygen concentration and proportional to the concentrations of forms able to donate an electron.

The mechanism of electron transport includes steps where highly active free radicals are formed. These radicals are capable of passing their unpaired high-energy electron directly to oxygen, thus producing superoxide anion radical and then the whole family of ROS such as OH radical and peroxides. The system of equations that constitutes this model is described in [17–19]. Parameter values for the respiratory chain used here were obtained from experimental studies [17] of normal mitochondrial function. The model calculates the levels of free radicals of the electron carriers constituting the respiratory chain (such as semiquinone radical). These radicals, normally formed in the process of electron transport, are responsible for ROS production. These levels are presented here as indicators of ROS production rate.

Overall, the mitochondrial ROS generation model produces two distinct patterns of response to $PmO_{2}$ at maximum exercise, as displayed in Figure 1. One pattern (HR) reflects above normal high ROS generation and the other (LR) reflects little or normal ROS generation. Briefly, the figure shows the rate of mitochondrial ROS production expressed as concentration of semiquinone radicals ($\mu$mol/mg) at $Qo$ site (ubiquinone binding site to complex III at the outer side of the inner mitochondrial membrane) of mitochondrial complex III ($y$-axis) against time ($x$-axis) for four different values of $PmO_{2}$, indicated in Figure 1.

Note that here, $PmO_{2}$ is expressed not as absolute values but as multiples of mitochondrial $P_{50}$ (in this case from $0.2P_{50}$ to $100P_{50}$). For pattern LR, there is essentially no change in ROS generation, and this corresponds to the two $PmO_{2}$ values exceeding the $P_{50}$ in Figure 1. Pattern HR is seen in the two examples where $PmO_{2}$ is less than $P_{50}$, and here a large, almost 10-fold increase in ROS generation occurs. In fact, the switch occurs abruptly when $PmO_{2}/3P_{50}$. The high sensitivity of mitochondrial ROS production to restrictions of oxygen transport, and thus to low $PmO_{2}$, is a consequence of multistationarity, the mechanisms of which are considered in detail in previous publications [17,18]. Finally, the increase in ROS generation persists after cessation of exercise, and the lower the $PmO_{2}$, the longer the persistence time, also shown in Figure 1.

The non-linear bi-stability inherent to mitochondrial ROS prediction model [17–19] accounts for the abrupt change of mitochondrial ROS production rate with a change of external (with respect to the respiratory chain) conditions. In principle such a change can be irreversible (in accordance with the phenomenon of bistability investigated in [17–19]), but in the considered case it reverses with a delay. The delay results from slow oxidation of

![Figure 1. Dynamics of ROS production (expressed as $SO_{2}$ produced, normalized to total complex III abundance (taken as 0.4 nmol/mg mitochondrial protein)) at four steady state concentrations of oxygen (expressed as mitochondrial $PO_{2}$ relative to $P_{50}$ the oxygen partial pressure at the half-maximal rate of respiration). Before and after exercise, rest is simulated (no ATP hydrolysis, proton gradient dissipates only due to membrane leak). Between 2 and 6.6 min, exercise is simulated (membrane proton gradient dissipates due to ATP hydrolysis and ATP synthase activity). Overall, ROS production falls into two distinct patterns: one (HR, seen when $PmO_{2}/P_{50} < 0.67$) reflects high ROS generation and the other (LR, when $PmO_{2}/P_{50} > 0.67$) reflects little or no ROS generation compared to rest. Note post-exercise persistence of high ROS generation, especially at the lowest $PmO_{2}$ to $P_{50}$ ratio. doi:10.1371/journal.pone.0111068.g001](image-url)
ubiquinol to ubiquinone, which is necessary to activate the Q-cycle in respiratory complex III.

Procedure for model integration

The use of \( P_{\text{mO}_2} \) normalized to \( P_{50} \) reflects the fact that while the model predicts different ROS generation rates at different \( P_{\text{mO}_2} \) values for a given mitochondrial respiration curve of any particular \( P_{50} \), when \( P_{\text{mO}_2} \) is the same fraction of \( P_{50} \), ROS generation is the same even if absolute \( P_{\text{mO}_2} \) and \( P_{50} \) are different. For example, if \( P_{\text{mO}_2} = 0.1 \) and \( P_{50} = 0.2 \), ROS generation would be the same as that computed when \( P_{\text{mO}_2} = 0.2 \) and \( P_{50} = 0.4 \), because in both cases, \( P_{\text{mO}_2}/P_{50} \) is the same (\( = 0.5 \)). This is illustrated in Figure 2, panels 1 and 2. In Panel 1, two mitochondrial respiration curves are drawn with the above different absolute \( P_{50} \) values (but the same \( V_{\text{max}} \) values). Using the above \( P_{\text{mO}_2} \) values, \( V_{\text{O}_2} \) in both cases would be the same at \( 1/3 \cdot V_{\text{max}} \), shown by the solid circles. Panel 2 replots these data normalizing the x-axis by \( P_{50} \) for each case, and normalizing the y-axis by \( V_{\text{max}} \) in each case.

These normalized respiration curves now overlie one another, and the important point is that the relative \( P_{\text{mO}_2} \) values, \( V_{\text{O}_2} \) in the two cases are identical and the relative \( V_{\text{max}} \) values are also identical, as will be ROS generation by the two regions. In a similar fashion, it is important to recognize that different muscle tissue regions may have different numbers of mitochondria and thus different \( V_{\text{max}} \) values even if \( P_{50} \) were uniform across regions. The normalization of \( V_{\text{O}_2} \) to \( V_{\text{max}} \) is thus necessary in order to compare different regions. For example, if \( V_{\text{O}_2} \) were the same at 0.2 units in two regions (and \( P_{50} \) were also the same in both regions) but \( V_{\text{max}} \) were different at 0.3 and 0.6 units in these two regions (Figure 2, panel 3), \( V_{\text{O}_2}/V_{\text{max}} \) in the first region would be 0.67 but only 0.50 in the second region. When the data are replotted to normalize \( P_{\text{mO}_2} \) (x-axis) to \( P_{50} \) and \( V_{\text{O}_2} \) (y-axis) to \( V_{\text{max}} \) (Figure 2, panel 4), the two solid circles now separate. Thus, despite similar absolute \( V_{\text{O}_2} \) values, and the same \( P_{50} \), the second region lies lower on the mitochondrial respiration curve than the first region.

Integration of the models

Recall that the oxygen pathway model consists of five equations, the solutions to which define the partial pressures of \( \text{O}_2 \) at each step between the air and the mitochondria as well as the mass flow of \( \text{O}_2 \) through the system (\( V_{\text{O}_2} \), \( V_{\text{max}} \)). Key input variables for this model are mitochondrial \( V_{\text{max}} \) and \( P_{50} \) (along with all of the conductances of the \( \text{O}_2 \) pathway). The key output variable for linkage to the metabolic model is \( V_{\text{O}_2} \), \( V_{\text{max}} \) (as a fraction of \( V_{\text{max}} \)). Thus, once the \( \text{O}_2 \) pathway model has been run for any

![Figure 2](https://www.plosone.org/doi/10.1371/journal.pone.0111068.g002)
set of input variables, the metabolic model accepts as inputs from the O2 pathway model $V_{O2}$ max, $V$ max, and mitochondrial $P_{50}$, which also then defines mitochondrial $P_{O2}$ from the hyperbolic mitochondrial respiration curve.

After scaling these variables to harmonize the units between the two models ($V_{O2}$ is in ml/min in the pathway model, but in nanomoles/min/mg mitochondrial protein in the metabolic model) the metabolic model is run, simulating mitochondrial respiration, i.e. the electron flow that reduces the transported oxygen to H2O. The principal outcome of the metabolic model for the present purposes is the rate of generation of ROS at exercise conditions for the given values of $V_{O2}$ max, $V$ max, $P_{50}$ and $P_{mO2}$.

Results

The main outcome of this study is allowing a quantitative analysis of how the physiological O2 transport pathway [10–12] affects mitochondrial ROS generation in muscle [17–19].

**Figure 3** shows how maximal $V_{O2}$ and mitochondrial $P_{O2}$ in a homogeneous muscle will fall together with altitude, as computed from the O2 pathway model. **Figure 3** also displays the degree of ROS generation as a function of mitochondrial $P_{O2}$ computed from the mitochondrial respiration model. As explained in [17–19], ROS generation abruptly switches from low to high levels when mitochondrial $P_{O2}$ reaches a critical value of 2/3 of the $P_{50}$ of the mitochondrial respiration curve – in **Figure 3** at about 0.1 mm Hg since $P_{50}$ is 0.14 mm Hg. In this case, the corresponding altitude is 24,000 ft. above sea level. Thus, open circles (altitudes less than 24,000 ft.) reflect a state of low ROS generation, and closed circles (altitudes greater than 24,000 ft.) reflect a state of high ROS generation. While **Figure 3** shows the outcome for a homogeneous muscle, in reality the muscles will not be perfectly homogeneous, just as no random group of humans will all have exactly the same height or weight. The important type of heterogeneity for O2 transport in muscle is that of the ratio of mitochondrial metabolic capacity ($V_{max}$, reflecting ability to consume O2) to blood flow ($Q$, reflecting O2 availability). Thus, with heterogeneity, some muscle regions will have lower than average $V_{max}/Q$ ratio, and other will have a $V_{max}/Q$ ratio greater than average. Data on the extent of heterogeneity in muscle are scarce due to lack of methods for its measurement, but recent, unpublished estimates based on near-infrared spectroscopy technology (Vogiatzis et al, J. Applied Physiol, under review) suggest that a small amount of heterogeneity does exist.

When $V_{max}/Q$ is high (metabolic capacity high in relation to O2 availability), mitochondrial $P_{O2}$ will be low, and vice versa as shown in **Figure 4** (simulated for several altitudes from sea level to 30,000 ft.). When expressed as the second moment of the $V_{O2}/Q$ distribution, on a log scale, the value is about 0.1. This can be compared to the identically computed and well-established index of ventilation/perfusion ($V_{AV}/Q$) inequality in the normal lung of 0.3-0.6 [31], which is generally regarded as small. **Figure 4** also shows the range of $V_{max}/Q$ ratios for a muscle with normal heterogeneity (i.e., dispersion of 0.1) as from about 0.15 to about 0.36, pointing out the large range of mitochondrial $P_{O2}$ that this seemingly small amount of heterogeneity creates. Thus, muscle regions with a high $V_{max}/Q$ ratio become susceptible to high ROS generation before those with lower $V_{max}/Q$ ratio. With the critical switch from low to high ROS production occurring at a $P_{mO2}$ of about 0.1 mm Hg, **Figure 4** shows that with normal heterogeneity, the muscle regions with highest $V_{max}/Q$ exhibit high ROS production already at 17,000 ft. altitude, and that at the summit of Mt. Everest (approx. 29,000 ft.), almost 100% of muscle regions will have switched to high ROS production.

**Figure 5A** shows the consequences of normal muscle $V_{max}/Q$ heterogeneity for the development of high ROS production in the format of **Figure 3**. The important points are: i) that due to the presence of high $V_{max}/Q$ regions, high ROS generation is seen (in those regions) already at 17,000 ft., a much lower altitude than for the homogeneous system (24,000 ft.), and ii) that high ROS generation becomes more extensive with further increases in altitude. **Figure 5B** shows the percentage of muscle predicted to have high ROS production over the altitude range from sea level to the Everest summit.

Discussion

The results displayed in **Figures 3–5** are specific to the input data used (Tables S1 and S2 in the supplementary on-line material). While they take advantage of the most complete data set available on humans exercising over a range in altitude from sea level to the equivalent of the Everest summit, the quantitative outcomes presented in this article would be different if a different data set were used. This should be kept in mind when interpreting the results presented. In addition, some specific, important data are both scarce in the literature and uncertain. The most important of these are the mitochondrial respiration curve characteristics (here defined by two parameters, $V_{max}$ and $P_{50}$, and the extent of heterogeneity in the distribution of blood flow to muscle regions with different metabolic capacity.

With respect to the mitochondrial respiration curve characteristics, in general, $P_{mO2}$ is systematically higher for the lowest $V_{max}$, and at any $V_{max}$, increasing mitochondrial $P_{50}$ results in systematically higher $P_{mO2}$ values. Because of uncertainty in $V_{max}$ and $P_{50}$ we carried out a sensitivity analysis that shows that in normoxia, as $V_{max}$ is varied from 10% to 20% to 30% above measured $V_{O2}$ max, oxygen transport and utilization is unaffected at 3.8 L/min. However, $P_{mO2}$ varies somewhat (1.2, 0.7, 0.5 mm Hg). At altitude, the effects were similar: at 15,000 ft. oxygen
Impact of Mitochondrial PO2 on ROS Generation

Biological and clinical implications

It is of interest that our results suggest that ROS generation in exercising normal muscle switches to high levels already at 17,000 ft., or about 5,000 m. This is the altitude above which permanent human habitation does not occur [35], and also the altitude above which humans experience inexorable loss of body mass. It is easy to hypothesize a cause and effect relationship between ROS and these findings, given the generally pro-inflammatory effects of high ROS levels, but whether this is indeed cause and effect or just coincidence remains to be established. In the same vein, the widespread presence of high ROS generation within muscle above 20,000 ft. and almost uniform presence above 25,000 ft. coincides with what is popularly termed the “death zone” in the mountaineering community – altitudes where fatalities are common. Of course, bitter cold, high winds, and hypoxia itself are likely contributors to the high risk of death under these conditions, but it is possible that high ROS production may be playing a role, not just in muscle but perhaps also in critical organs such as the brain. There is a growing body of literature [36–38] suggesting that endogenous ROS at high concentrations are damaging to cells, while at lower levels they are involved in activating important signaling pathways, some of which relate to adaptation to hypoxia (angiogenesis, for example where the promoter region of the critical angiogenic gene VEGF has a binding site for H2O2 [39]. They also act as pro-survival molecules regulating kinase-driven pathways [36,40]. A recent systems analysis of abnormal muscle bioenergetics in patients with Chronic Obstructive Pulmonary Disease (COPD) [41] provides indirect evidence for a central role of cellular hypoxia in explaining abnormal regulation of key metabolic networks regulated by genetic and epigenetic mechanisms. Moreover, there is evidence [42–44] of the role of nitroso-redox disequilibrium explaining systemic effects in several chronic disorders such as COPD, chronic heart failure and type II diabetes. However, current knowledge of mitochondrial dysfunction [45–47] is still incomplete. The centrality of oxygen metabolism in organisms leads to the notion that it is also involved in other complex chronic diseases at essentially every level of organization [5,48–50].

Potential applications of the integrated transport/metabolic model, which has been presented here only in terms of healthy humans at altitude, are envisioned in systems medicine with analysis of the potentially greater degree of ROS generation associated with impaired O2 availability in patients with diseases such as COPD, heart failure, diabetes and peripheral vascular disease. With the necessary input data, this could be done for individual patients to assess the likelihood of high ROS generation in muscle. In addition, the model may allow the prediction of the benefits of exercise programs and pharmacological interventions in these patients. Through its predictions, the current analysis may open new avenues in assessment of the impact of impaired oxygen exchange on increased mitochondrial ROS generation as well as in evaluation of the consequences of oxidative stress on biological consumption was invariant at 2.8 L/min and $P_{Mo2}$ was 1.9, 1.6, 1.3 mm Hg respectively; while at 30,000 ft, oxygen consumption remained invariant at 1.4 L/min with $P_{Mo2}$ values of 0.07, 0.06, 0.06 mm Hg respectively. At any altitude, therefore, prediction of ROS generation was not affected by this degree of uncertainty in $V$ max.

When $P_{50}$ was varied between 0.1 and 1.0 mm Hg, oxygen utilization was minimally affected (3.8 to 3.6 L/min respectively) while $P_{Mo2}$ increased from 0.5 to 3.7 mm Hg. Considered relative to $P_{50}$, which is what is important in ROS generation as discussed above, $P_{Mo2}/P_{50}$ decreased from 4.9 to 3.7. At 15,000 ft. oxygen utilization fell from 2.8 to 2.7 L/min as $P_{50}$ was raised from 0.1 to 1 mm Hg and $P_{Mo2}$ increased from 0.2 to 1.5 mm Hg. When normalized to $P_{50}$, $P_{Mo2}$ was invariant at 1.5-$P_{50}$. At 30,000 ft. oxygen utilization was unaffected as $P_{50}$ was varied from 0.1 to 1 mm Hg (at 1.4 L/min), while $P_{Mo2}$ increased from 0.05 to 0.45 mm Hg. However, when normalized to $P_{50}$, $P_{Mo2}$ was invariant at 0.45-$P_{50}$. Thus, variation in $P_{50}$ over a 10-fold range did not affect the outcome in terms of ROS generation.

While the particular results we report depend on the values we took for these functions, the important point is the presentation of the integrated model approach coupling physiological elements of O2 transport with biochemical elements of oxidative phosphorylation stands, no matter what specific data are used to run it. A graphical user interface to parameterize and simulate the integrated model is freely available at https://sourceforge.net/projects/o2ros.
functions in different acute and chronic diseases [5,6]. While prediction of mitochondrial ROS generation may be possible, it is clear that the current integrated model addresses only the relationships between determinants of cellular oxygenation and mitochondrial ROS production. It does not attempt to deal with other sources of ROS [51] or complexities of the redox system such as the antioxidant resources that will modulate the biological activity of ROS generated by exercise within muscle, and which will thus affect oxidative stress. Accounting for such elements is well beyond the scope of this article, but it’s a target for the future.

Conclusions

The integration of the two deterministic modeling approaches considered in this study allows us to establish a quantitative analysis of the relationships between the components of the O2 pathway [10–12,16] and mitochondrial ROS generation [17–19]. To this end, the simulations herein using data from exercising normal subjects at sea level and altitude have shown that when $\dot{V}_{O2}$ is low (less than 40% of mitochondrial oxidative capacity) due to impaired O2 transport, extremely low PmO2 values will develop, which in turn may be associated with above normal ROS production. This will occur when PmO2 < 2/3 of mitochondrial $P_{50}$. The current investigation may open new avenues for assessing the impact of impaired oxygen transport on increased mitochondrial ROS generation as well as for evaluating the consequences of oxidative stress on biological functions in both acute and chronic diseases [5,6].

Supporting Information

Table S1 Input parameters for the oxygen transport system. Values interpolated from those measured during OEII (reference at sea level, 15,000 ft, 20,000 ft, 25,000 ft and 29,000 ft).

(DOCX)

Table S2 Input parameters for the modeling of Cell Bioenergetics and ROS production.

(DOCX)
Author Contributions
Conceived and designed the experiments: IC PDW VS MC JR DGC JT. Performed the experiments: IC PDW VS. Analyzed the data: IC PDW VS.

References

1. Waypa GB, Marks JD, Guzy R, Mungai PT, Schriewer J, et al. (2010) Hypoxia triggers subcellular compartmental redox signaling in vascular smooth muscle cells. Circ Res 106: 526–535.
2. Bailey DM, Young BS, McEneny J, Lawrenson L, Kim J, et al. (2004) Regulation of free radical nitrosylation of an isolated muscle bed in exercising humans. American Journal of Physiology - Heart and Circulatory Physiology 287: H1609–H1699.
3. Koechlin C, Maltas F, Saey D, Michael A, LeBlanc P, et al. (2005) Hypoxemia enhances peripheral muscle oxidative stress in chronic obstructive pulmonary disease. Thorax 60: 834–841.
4. Cherniack NS (2004) Oxygen sensing: applications in humans. Journal of Applied Physiology 96: 332–338.
5. Seneza GN, Kim Oxygen Sensing, Homeostasis, and Disease. New England Journal of Medicine 365: 537–547.
6. Schumacker PT (2011) Lung cell hypoxia: role of mitochondrial reactive oxygen species signaling in triggering responses. Proc Am Thorac Soc 8: 477–484.
7. Richardson RS, Noyszewski EA, Kendrick KF, Leigh JS, Wagner PD (1995) Myoglobin O2 desaturation during exercise. Evidence of limited O2 transport. J Clin Invest 96: 1916–1926.
8. Tran TK, Slaouta N, Hurld T, Jue T (1999) Spatial distribution of deoxyhaemoglobin in the human muscle: an index of local tissue oxygenation. NMR Biomed 12: 26–30.
9. Mik EG (2013) Measuring Mitochondrial Oxygen Tension: From Basic Principles to Application in Humans. Anesth Analg 117: 833–846.
10. Wagner PD (1996) Determinants of maximal oxygen transport and utilization. Annu Rev Physiol 58: 21–50.
11. Wagner PD (1993) Algebraic analysis of the determinants of VO2max. Respir Physiol 93: 221–237.
12. Cano I, Mickael M, Gomez-Cabrero D, Tegne´r J, Roca J, et al. (2013) Importance of mitochondrial in maximal O2 transport and utilization: A theoretical analysis. Respiratory Physiology & Neurobiology 189: 477–483.
13. Wilson DF, Erecinska M, Drown C, Silver LA (1977) Effect of oxygen tension on cellular energetics. American Journal of Physiology - Cell Physiology 233: C135–C149.
14. Gough DR, Cotter TG (2011) Hydrogen peroxide: a Jekyll and Hyde signalling molecule. Cell Death and Dis 2: e213.
15. Simon HU, Haji-Yehia A, Levi-Schaffer F (2000) Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 5: 415–418.
16. Kudla MA, So EY, Simons AL, Spitz DR, Oschi T (2012) DNA damage induces reactive oxygen species generation through the H2AX-Nox1/Rac1 pathway. Cell Death Dis 3: e249.
17. Oshikawa J, Urao N, Kim HW, Kaplan N, Razvi M, et al. (2010) Extracellular SOD-derived H2O2 promotes VEGF signaling in caveolae/lipid rafts and post- ischemic angiogenesis in mice. PLoS One 5: e10189.
18. Giampoli E, Buricchi F, Raugei G, Ramponi G, Chiarelli P (2005) Intracellular reactive oxygen species activate Src tyrosine kinase during cell adhesion and anchorage-dependent cell growth. Mol Cell Biol 25: 6391–6403.
19. Turan N, Kalko S, Sirinec A, Clarke K, Sahah A, et al. (2011) A Systems Biology Approach Identifies Molecular Networks Defining Skeletal Muscle Abnormalities in Chronic Obstructive Pulmonary Disease. PLoS Comput Biol 7: e1002129.
20. Rodriguez DA, Kalko S, Puig-Vilanova E, Perez-Obalbara M, Falciani F, et al. (2010) Muscle and blood redox status after exercise training in severe COPD patients. Free Radic Biol Med 52: 86–94.
21. Havre JM (2004) Nitroso-Redox. Balance in the Cardiovascular System. New England Journal of Medicine 351: 2112–2114.
22. Singel DJ, Stannier JS (2004) Blood traffic control. Nat. 430: 297–297.
23. Rabinovich R, Basts R, Aridte E, Llina`s L, Orozco-Levi M, et al. (2007) Microvascular mitochondrial dysfunction in COPD patients with low body mass index. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology 29: 643–650.
24. Puente-Maestu L, Perea-Parra J, Godoy R, Moreno N, Tejedor A, et al. (2009) Alveolar transition pore kinetics and cytochrome C release in muscle mitochondria of patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 40: 746–750.
25. Meyer A, Zoll J, Charles AL, Charlois A, de Blay F, et al. (2013) Skeletal muscle mitochondrial dysfunction during chronic obstructive pulmonary disease: central actor and therapeutical target. Exp Physiol 98: 1063–1078.
26. Raymond J, Segre D (2006) The effect of oxygen on biochemical networks and the evolution of complex life. Science 311: 1764–1767.
27. Baldwin JE, Krebs H (1981) The evolution of metabolic cycles. Nature 291: 381–382.
28. Koch LG, Britton SL (2008) Aerobic metabolism underlies complexity and capacity. J Physiol 596: 83–95.
29. Powers SK, Nelson WB, Hudson MB (2011) Exercise-induced oxidative stress in humans: cause and consequences. Free Radic Biol Med 51: 942–950.

Contributed reagents/materials/analysis tools: IC PDW VS. Wrote the paper: IC PDW VS MC JR DGC JT.